Order Now 1-800-246-8878

End-to-end NGS solutions and gene panels powered by XNA technology

OptiSeq™ NGS Targeted Sequencing Service Platform

No more costly and time-consuming deep sequencing! DiaCarta’s OptiSeq™ Next-Gen sequencing platform removes the cost and time barriers by reducing the sequencing depth by a factor of up to 100X and enabling ultra-sensitive detection of genetic mutations. The platform combines with the proprietary XNA technology that only hybridizes the wild-type template. That way, only the mutant template is amplified and sequenced. 500 sequencing reads on the OptiSeq™ platform are equivalent to 50,000 reads without using the platform.

OptiSeq™ gene panels

CLIA Validated Gene Panel 
• OptiSeq™ Pan-Cancer Panel (65 Genes)

Research-Use-Only Validated Gene Panel
• OptiSeq™ Lung Cancer Panel (29 Genes)

Customized Gene Panels
• OptiSeq™ Actionable Panel (12 Genes)                             • OptiSeq™ Prostate Panel (32 Genes)
• OptiSeq™ Target Panel (33 Genes)                                    • OptiSeq™ Colon Panel (38 Genes)
• OptiSeq™ Comprehensive Panel (76 Genes)                    • OptiSeq™ Breast Panel (44 Genes)

Features and benefits


Ability to detect below 0.1% mutations

Sample Format

Suitable for FFPE tissue (e.g. solid tumor) and blood samples (e.g. ctDNA)


Streamlined workflow with 7-10 days turnaround time from sample to report


Fewer errors by enriching mutant allele reads


Robust XNA-PCR minimizes variability

Cost Effective

Achieve by reducing 100x read depth

Supporting data

Melting Profiles of PCR Amplicon
OptiSeq™ applies XNA-PCR to predominantly enrich the KRAS codon 12 mutant allele from a lung tumor sample, resulting in a pure mutant PCR amplicon as indicated by a single peak in the high-resolution melting profile (on the left). PCR for conventional NGS  however, obscures the mutant allelic signal in the profile (on the right).

Ultra Sensitive Detection of BRAF V600 Mutation
Ultra-sensitive detection of rare and actionable mutations is achieved without deep sequencing. OptiSeq™ rapidly, precisely and cost-effectively detects the BRAF V600E mutation from ctDNA in whole blood. Shown is the detection levels of 5%, 1% and 0.1% mutant DNA, respectively.

OptiSeq™: Background Noise Reduction
Data comes from circulating tumor DNA mutation sites. It presents high background noise from wild-type DNA (filled and open circle below the dotted line) separated from mutant DNA signal (inverted triangle above dotted line). For mutant DNA, only variant DNA template sequences are sequenced/analyzed. 500 reads OptiSeq™ = 50,000 reads without XNA technology. For wild-type DNA, wild-type alleles are not analyzed so reduces real-time but still gives high-quality read dept